Skip to main content
OpenTrials
Completed

NCT Number: NCT02349815

JAYDESS Drug Utilization Study in Sweden

* To describe characteristics (demographic, clinical, social) of first time users of Jaydess * To estimate the duration of use of Jaydess * To study switching patterns, e.g. what are the hormonal contraceptive methods used before and what are the methods after discontinuing Jaydess * To study off-label use of Jaydess

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraception

Age range

18 year–64 year

Sex eligibility

Female

Study type

Observational

Primary location

Many Locations

Multiple Locations, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Swedish women who were dispensed a JAYDESS from a Swedish Pharmacy anytime 2014-2017

Exclusion criteria

No exclusion criteria

Treatment and study plan

Levonorgestrel (Jaydess, Skyla, BAY86-5028)

Drug

Women use Levonorgestrel (Jaydess, BAY86-5028) .

Primary outcomes

  1. Duration of use of JAYDESS

    Time frame: Up to 6 years

  2. Indication for use

    Time frame: At insertion

Secondary outcomes

  1. Age at insertion and removal

    Time frame: Up to 6 years

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Collaborators

  • Karolinska Institutet

Registry information

Official study title

Pharmacoepidemiological Study (Drug Utilization Study) of JAYDESS Use in Routine Clinical Practice in Sweden

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Jan 29, 2015
Registry last updated
Jan 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.